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Commentary
Timely development of vaccines against SARS-CoV-2
Shan Lu
Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA
The rapidly emerging SARS-2-CoV (SARS-2) has been
spreading through China and entering many parts of
the world with easy human-to-human transmission
and thousands of deaths [1–10]. Development of a vac-
cine, and a vaccine which can be quickly deployed on a
global scale, is no longer merely a discussion or part of
a debate whether such a vaccine is ultimately needed.
Why is a vaccine needed?
While the ﬁrst wave of this outbreak appears to be
under control in many parts of China, there are a num-
ber of remaining concerns:
1. When will new cases of infection stop emerging
from the “ground zero” Wuhan City? Since the
real origin of infection is still not fully conﬁrmed,
a complete control of infection in Wuhan is essen-
tial for a sustained control in the whole country.
2. Will therebeanynear-termresurgingof cluster cases in
other parts of China, including regions in Hubei
beyond Wuhan, capital of the province? The random
cases can be quickly put under control given the highly
alert local monitoring systems and well-practiced
healthcare teams’ eﬀective work over the last several
weeks. But the cluster cases may pose a new threat for
their potential to generate another regional outbreak.
3. Will the world, especially those countries less pre-
pared or with less healthcare resources, be able to
handle the sudden appearance of cases at their
doorstep? The assumption of persistent trans-
mission of SARS-2 at a global scale may no longer
be so far-fetched. Even if the virus does not bring
a high mortality, the scenario of Community
Acquired Coronavirus Infection (CACI) caused by
a SARS type virus as part of our daily life will likely
disrupt the world social and economic order.
The same calls for vaccines against SARS and Zika
faded after the peak of those mysterious outbreaks, par-
tially due to no public demand or limited commercial
return to the vaccine investment. However, a timely
development of vaccines against SARS-2 is needed
this time, not only for controlling the infection but
also for stabilizing the global mood and bringing the
economy back on track.
The current eﬀorts to quickly develop a
SARS-2 vaccine
The good news now is that many entities have taken
actions. CEPI (Coalition for Epidemic Preparedness
Innovations) [11] announced on January 23, 2020, the
funding to three platform vaccine technologies, DNA,
mRNA, and “molecular clamp”, to develop vaccines
against SARS-2. CEPI’s mission is to “accelerate the
development of vaccines against emerging infectious dis-
eases and enable equitable access to these vaccines for
people during outbreaks.” The current outbreak will be
theﬁrstmajor test toCEPI since its establishment in 2017.
There is a growing list of global public and private
institutions joining the eﬀorts to develop vaccines against
SARS-2. The US NIAID Vaccine Research Centre
(VRC) is drawing on broad research experience with
coronaviruses, combined with a wide network of collab-
orators from academia, other government agencies, and
industry, on the development of various SARS-2 vaccine
candidates. Biotech and traditional vaccine companies in
many countries announced their plans to quickly
develop vaccines using their respective technologies.
From very early in the onset of this outbreak, China
demonstrated conﬁdence in developing a vaccine against
this viral infection. More recently, the oﬃcial announce-
ment by the Chinese Health Commission indicated that
at least ﬁve vaccine technologies will be explored: inacti-
vated vaccine, subunit protein vaccine, nucleic acid vac-
cine, adenoviral vector vaccine, and recombinant
inﬂuenza viral vector vaccine. With the growing size of
the domestic vaccine industry in recent years, China vac-
cine developers are expected to announce multiple lead-
ing candidate vaccines in the near future.
What are the challenges
The vaccine industry based on the empirical technol-
ogy has made major contributions to human health
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over the last 100 years. However, vaccine science is
still young in light of the modern immunology and
molecular microbiology which have contributed to
the requirement of a longer time to develop a new
vaccine. Enhanced safety concerns, increasingly com-
plicated manufacturing processes, and related assay
requirements are adding to the time and cost for
new vaccine development. A new set of rules and
standards will need to be adopted to balance the
competing scientiﬁc, technical, regulatory, and public
health considerations, if a quick response SARS-2
vaccine needs to be developed for near future clinical
use.
In recent years, immune correlates of protection are
increasingly asked for a candidate vaccine [12]. Struc-
ture-guided antigen design is quite common. At the
same time, vaccine development is still far from
being a perfect science. The discontinuation of
HVTN702 reported within the last few weeks
reminded us again of the big gap between science
and the development of an HIV vaccine after almost
four decades’ eﬀort. Will protective antibody responses
be the targeted immune responses for various vaccine
programs against SARS-2? Given the potential chal-
lenge in quickly organizing eﬃcacy studies, the animal
models against challenge will be extremely valuable for
selecting the candidates into humans.
Traditional vaccine technologies need improve-
ment and a wide variety of new technologies have
emerged in the last two decades [13]. Given the
unique requirements of a vaccine against the rapidly
spreading emerging viral infection, vaccine technol-
ogies with previous human study experience will
have the advantage, especially for the consideration
of safety. Furthermore, whether the developer can
quickly move its vaccine technology into a scale-up
GMP production for potentially 10-million doses is
another challenge. Anyone with an existing facility
and the experience of such production will be in a
much more favourable position.
The challenge to the regulatory agencies for a timely
SARS-2 vaccine is similar to that of the vaccine devel-
opers. Safety evaluation of a candidate vaccine against
SARS-2 will receive high-level attention. The immuno-
pathogenesis plays a major role in SARS-2 infection
and thus it is important to ensure that vaccines against
this virus should not elicit the same type of detrimental
immune responses. This will aﬀect the type of vaccines
to be selected and immunogens to be designed. Will a
qualiﬁed manufacturing process be suﬃcient for the
advancement of a candidate vaccine or it has to be vali-
dated? Can the manufacturing and regulatory experi-
ence achieved in other countries be applied to the
review of a vaccine application in the current country?
Can the cell banks or other intermediate products be
accepted across country borders? Will the political or
commercial considerations become the barriers to the
global eﬀort in addressing the urgent need of a
SARS-2 vaccine?
Finally, the planning should start now on how to let
the world have equal access to a successful SARS-2 vac-
cine if the need is global. The following issues need to
be addressed: vaccine ownership, the funding for pro-
duction at an unprecedented scale, the pricing and
supply chain, and the coordinated administration of
such a vaccine to achieve the best outcome of full con-
trol of the endemic.
A vaccine beyond the current outbreak
Even if the global spread of SARS-2 is ﬁnally under
control before a successful vaccine is fully developed,
the vaccine community and world public health leaders
need to decide whether a SARS-2 vaccine still should be
licensed to serve as a template for vaccines in the future
to prevent the outbreaks of other SARS-like viruses.
Within 18 years, the world has witnessed three major
emerging pathogenic beta coronaviruses (SARS,
MERS, and SARS-2) entering large human popu-
lations. It may not be too ambitious to suggest a vaccine
that can provide broad coverage against more than one
of these pathogenic viruses to prevent for future
outbreaks.
It is generally agreed that developing a new vaccine
needs many years’ eﬀorts. However, the development
of vaccines in recent years against EV71, a highly
pathogenic virus causing severe Hand, Foot and
Mouth Disease (HFMD) in children, has provided a
good example that it is possible to develop a vaccine
against a modern emerging infection [14,15]. Hope-
fully, it can be even faster this time and possibly
using newer vaccine technologies.
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